Kenvue Inc. $KVUE Shares Purchased by DNB Asset Management AS

DNB Asset Management AS raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 388,475 shares of the company’s stock after purchasing an additional 6,311 shares during the quarter. DNB Asset Management AS’s holdings in Kenvue were worth $8,131,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after buying an additional 10,600,682 shares during the period. Third Point LLC bought a new stake in Kenvue in the first quarter worth about $213,422,000. Maverick Capital Ltd. acquired a new stake in Kenvue in the 1st quarter valued at about $203,036,000. Nuveen LLC bought a new position in shares of Kenvue during the 1st quarter valued at about $187,123,000. Finally, Voya Investment Management LLC grew its stake in shares of Kenvue by 131.3% in the 1st quarter. Voya Investment Management LLC now owns 12,131,468 shares of the company’s stock worth $290,557,000 after purchasing an additional 6,886,784 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $16.63 on Friday. The company’s fifty day moving average is $16.17 and its two-hundred day moving average is $19.80. The company has a market cap of $31.86 billion, a P/E ratio of 22.17, a price-to-earnings-growth ratio of 2.31 and a beta of 0.71. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.Kenvue’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be issued a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.0%. Kenvue’s dividend payout ratio is currently 110.67%.

Analysts Set New Price Targets

Several analysts recently commented on KVUE shares. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Evercore ISI set a $18.00 target price on Kenvue in a report on Tuesday, October 28th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $15.00 target price (down from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Finally, Bank of America decreased their price target on Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.